Dr. Grennan's research interests include HIV and STI prevention, HPV-associated disease and anal cancer, and the health of men who have sex with men (MSM). He currently holds several grants in these areas. He is the co-principal investigator on two CIHR-funded grants. The first, the Doxycycline as an Intervention for STI Chemoprophylaxis (DISCO) study is a national, multi-centre randomized controlled trial examining the novel use of a common antibiotic for the prevention of bacterial STIs. The second, the Predicting and Evaluating Anal Cancer in HIV using novel biomarkers (PEACH) study, is a cohort study examining the predictive ability of various HPV biomarkers in predicting anal pre-cancers in MSM and trans women living with HIV, the group most disproportionately impacted by anal cancer.
Dr. Grennan received his medical degree from McMaster University. This was followed by internal medicine training at the University of Toronto, infectious diseases and medical microbiology training at McMaster University, a post-doctoral fellowship from the CIHR Canadian HIV Trials Network and a masters degree in clinical epidemiology from the University of Toronto, where his research project focused on HPV in HIV-positive MSM.
Prior to his arrival in BC in January 2015, his work centred mainly around clinical HIV, STI and other infectious diseases, as well as anal cancer screening. In addition to his role at the BCCDC, he works in the anal cancer screening clinic at St. Paul's Hospital.
